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Abstract: It is hard to imagine that all the cells of the human organism (about 10
14) share identical genome. Moreover, 
the number of mitoses (about 10
16) required for the organism’s development and maturation during ontogeny suggests that 
at least a proportion of them could be abnormal leading, thereby, to large-scale genomic alterations in somatic cells. Ex-
perimental data do demonstrate such genomic variations to exist and to be involved in human development and interindi-
vidual genetic variability in health and disease. However, since current genomic technologies are mainly based on meth-
ods, which analyze genomes from a large pool of cells, intercellular or somatic genome variations are significantly less 
appreciated in modern bioscience. Here, a review of somatic genome variations occurring at all levels of genome organi-
zation (i.e. DNA sequence, subchromosomal and chromosomal) in health and disease is presented. Looking through the 
available literature, it was possible to show that the somatic cell genome is extremely variable. Additionally, being mainly 
associated with chromosome or genome instability (most commonly manifesting as aneuploidy), somatic genome varia-
tions are involved in pathogenesis of numerous human diseases. The latter mainly concerns diseases of the brain (i.e. 
autism, schizophrenia, Alzheimer’s disease) and immune system (autoimmune diseases), chromosomal and some mono-
genic syndromes, cancers, infertility and prenatal mortality. Taking into account data on somatic genome variations and 
chromosome instability, it becomes possible to show that related processes can underlie non-malignant pathology such as 
(neuro)degeneration or other local tissue dysfunctions. Together, we suggest that detection and characterization of somatic 
genome behavior and variations can provide new opportunities for human genome research and genetics. 
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INTRODUCTION 
  The human organism consists of about 10
14 cells of 210 
different types that originate from one zygote and are the 
result of about 10
16 mitoses (approximately 45 cellular gen-
erations). Moreover, the large number of cellular divisions is 
required to maintain relatively stable amount of cells in a 
human body to cover each day’s loss of more than several 
tens of millions of cells. These numbers make clear that such 
an “amount of processes” cannot be identically reproduced 
and, therefore, all the cells of an organism are unlikely to 
possess identical genomes.  
  It appears that the most critical period for somatic muta-
tions to occur is early embryonic development [1, 2]. Char-
acterized by the logarithmic increase in cells (the most dra-
matic increase of cell numbers in human ontogeny) [2], hu-
man embryos are thought to exhibit increased levels of mi-
totic mutations [3-5]. This is experimentally confirmed by 
molecular cytogenetic studies of embryonic and fetal cells, 
which demonstrate high rates of aneuploidy due to mitotic 
errors correlated with high cell division rate [5, 6]. There-
fore, genetically altered cells produced during this ontoge-
netic period form a basis for organism dysfunction at the 
following developmental stages [3, 4, 7]. Nonetheless, there  
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is still a possibility that somatic genome variations (SGV) 
lack adverse effect due to natural selection and clearance of 
abnormal cells [5, 4, 7, 8]. 
  The genome of a cell is supposed to experience 10
4-10
5 
of DNA lesions per day. This is another source (exogenous 
source) for cellular genome to change and, if remains unre-
paired (uncleared), such genomic variations give rise to 
pathogenic processes (i.e. cancerization) [9]. Although this is 
a likely process for diseases caused by SGV produced 
through either genomic instability (GIN) or chromosome 
instability (CIN) [7-12], it is supposed to be an underlying 
mechanism of human aging [8, 11]. 
  Despite of numerous attempts to highlight the role of 
SGV [2-8, 10, 12-22], related phenomena remain largely 
underappreciated in current biomedical literature. This sug-
gests that an additional attention to SGV is required. Hence, 
a review of SGV might help to define the contribution to 
human interindividual diversity in health and disease. 
NATURAL SGV 
  Since benign genomic variations of somatic genome re-
main to be poorly described, it is hard to assess the effect of 
SGV on the non-pathogenic diversity. Thus, no less than 
12% of the human genome encompassing disease-associated 
loci is diversified between two individuals [23]. Although it 
is difficult to extrapolate these data to cell populations, it can 
be considered as an indirect evidence for cellular genome to 
change in a related manner. Fortunately, there are molecular 388    Current Genomics, 2010, Vol. 11, No. 6  Iourov et al. 
Table 1.  SGV in Normal Human Tissues 
Tissue/Cell type  Type of SGV  Description  Key Refs 
Aneuploidy  15-91% of samples (mean is about 50%)  [6, 25, 26] 
Preimplantation embryos 
Structural rearrangements, aneuploidy, CNV*, segmen-
tal duplications, uniparental disomy 
>90% of samples (83% — aneuploidy)  [6] 
Embryos/Fetuses (7-12 weeks) 
Cytotrophoblasts Aneuploidy  20-60%  of  cells  [27] 
Brain  Aneuploidy  1.45% of cells^  [5, 28] 
Chorionic villi  Aneuploidy  0.98% of cells^  [5] 
Skin Aneuploidy  0.82%  of  cells^  [5] 
Ovarian tissue  Trisomy of chromosome 21 (aneuploidy) 
Statistically significant increase of ane-
uploid cells 
[29] 
Prenatal diagnosis: CVS** or Amniocentesis 
Amniocytes Aneuploidy  0.25%  of  samples  [30] 
Chorionic villi/Placenta  Aneuploidy  1-2% of samples  [31, 32] 
Newborns/Children 
Blood lymphocytes  Aneuploidy  >0.1% (clinical population?)  [4, 33, 34] 
Blood lymphocytes  Aneuploidy 
0.73% (autosomes) and 1.11% (chromo-
some X) of cells — unaffected population^ 
[35] 
Blood lymphocytes  Structural rearrangements  0.01% (clinical population?)  [36] 
Adults (middle age) 
Blood lymphocytes  Aneuploidy  1-3% of cells^  [37-39] 
Blood lymphocytes  Structural rearrangements  0.6% of cells  [40] 
Skin fibroblasts  Aneuploidy  2.2% of cells^  [41] 
Liver Aneuploidy  3%  of  cells^  [42] 
Brain  Aneuploidy  0.3-0.9% of cells^  [10, 28, 43-45] 
Brain 
Skin 
Heart 
Kidney 
Liver 
CNV* 
Tissue-specific CNV; amount of cells and 
percentage of samples was not available 
[46] 
T-lymphocytes 
Imortalized B lymphoblas-
toid cells 
Skin fibroblasts 
Subtle structural rearrangements or CNV 
Tissue-specific mosaicism probably origi-
nating from developmental chromosome 
instability 
[47] 
Adults (aged individuals) 
Blood lymphocytes  Aneuploidy 
1-2% (autosomes) and 4-7% (chromosome 
X) of cells^ 
[37-39] 
Skin fibroblasts  Aneuploidy  4.4% of cells^  [41] 
Brain  Aneuploidy  0.3-0.9% of cells^  [10, 28, 43-45] 
* — copy number variations; ** — chorionic villus sampling; ^ — per chromosome. Somatic Genome Variations in Health and Disease  Current Genomics, 2010, Vol. 11, No. 6    389 
cytogenetic data on SGV manifested at chromosomal level 
(structural rearrangements, aneuploidy and polyploidy) in 
early prenatal development. As to other types of genomic 
variations, including single-base DNA changes, DNA se-
quence deletion/duplications/inversions, repeat expansions, 
transposition of mobile DNA elements, copy number varia-
tions (CNV), chromosomal miscrodeletions/microduplica-
tions (for more details see reviews [15, 24]), their incidence 
among human fetuses remain largely unknown. SGV de-
tected after birth (non-affected individuals) are mainly re-
ferred to low-level mosaic aneuploidy [3, 4, 7]. Mosaic 
structural genomic rearrangements at chromosomal level are 
also reported, being, however occasionally detected. Addi-
tionally, the best documented SGV are tissue-specific varia-
tions of chromosome numbers (aneuploidy) and CNV. Table 
1 gathers the data on SGV in normal human tissues (cell 
types). 
  The essential problem surrounding the evaluation of SGV 
is a technological one (for more details see [3, 4, 7, 15, 18, 
22, 24]). In other words, some tissues or developmental 
stages were evaluated using single-cell high-resolution mo-
lecular cytogenetic techniques, whereas others were not [22]. 
Therefore, it is hard to compare different data on SGV. Nev-
ertheless, preimplantation embryos exhibit high rates of SGV 
manifested at chromosomal (microscopic and submicro-
scopic) level including aneuploidy, gross structural genomic 
rearrangements, CNV, segmental duplications. In total, it is 
estimated that almost 90% of samples have cells with differ-
ent genomes [6, 25, 26]. The intercellular rate of variations 
(percentage of abnormal cells) is uninformative because of 
small amount of cells at this developmental stage [3, 4]. At 
the next stages of prenatal development, a lesser frequency 
of SGV is observed, being, still, appreciable and affecting up 
to 30% of fetuses (aneuploidy) [4, 5, 8]. This is observed in 
extraembrionic tissues [5, 27] and is suggested to play a key 
role in normal human placentation [27]. Additionally, no less 
than 30-35% of cells of the developing human brain and 
20% of fetal skin are aneuploid [5, 28]. Finally, fetal ovarian 
tissues demonstrate a significant increase of mosaic trisomy 
of chromosome 21 [29]. Further periods of human intrauter-
ine development ascertained through prenatal diagnosis 
(chorionic villus sampling (CVS) and amniocentesis) show a 
small rate of SGV [30]. However, it is to note that these pe-
riods are rarely evaluated by molecular cytogenetic tech-
niques (singular case-reports only), which are essential for 
accurate SGV detection [3, 22]. An additional issue of such 
studies is description of another example of apparently be-
nign tissue-specific SGV in human fetuses referred to as 
placental mosaicism [31, 32]. Together, SGV appear to be 
mainly formed during prenatal development and have the 
potential to give rise to intercellular diversity after birth in 
health and disease. 
  Newborns were not thoroughly evaluated in terms of 
SGV. Furthermore, the only available data on large genomic 
variations (chromosomal abnormalities and heteromorphism) 
can be only acquired from papers describing banding studies 
performed in the end of 70s or beginning of 80s [4, 33, 34]. 
Chromosomal mosaicism detected by banding cytogenetics 
in newborns is less frequent than 0.1% [33, 34]. Molecular 
cytogenetic evaluations of control group in a survey of SGV 
in autism showed rates of mosaic aneuploidy in blood lym-
phocytes as 0.73% (autosomes) and 1.11% (chromosome X) 
[35]. Mosaic structural chromosome rearrangements are ex-
tremely rare and are supposed to be detected in a clinical 
population only [36]. Middle age adults exhibit 1-3% of ane-
uploid cells in tissues composed of mitotically active cells 
and less than 1% in the adult human brain, which is mainly 
composed of post-mitotic cells [10, 28, 37-45]. Natural SGV 
manifesting as structural rearrangements detectable by band-
ing cytogenetics in blood lymphocytes achieve the rate of 
0.6% [40]. Mosaic subtle structural genomic rearrangements 
and CNV can be tissue-specific in presumably unaffected 
individuals [46, 47]. Aged human tissues are known to be 
featured by increased rates of SGV essentially manifesting as 
low-level mosaic aneuploidy [8, 10, 28, 37-39, 41, 43-45]. In 
conclusion, three main features of natural human SGV may 
be highlighted: (i) SGV do contribute to human natural (in-
tercellular) genomic variation; (ii) further studies are 
strongly required to identify incidence and possible effect of 
SGV on unaffected human tissues; (iii) SGV have different 
rates at different ontogenetic stages. The latter suggests a 
role for SGV in human development and aging. 
SGV AND DEVELOPMENTAL/AGING PROCESSES 
  Although involvements of SGV in developmental and 
aging processes are presented in another review published in 
this Hot Topic Issue (YB Yurov et al. Ontogenetic variation 
of the human genome), we found needful to mention briefly 
related phenomena. This appears to be important for further 
delineation of the role of SGV in human diseases and 
mechanisms of SGV formation. Two kinds of fates of ab-
normal cells formed during early prenatal development are 
hypothesized: persistence (increase or stability of rates) and 
clearance (decrease of rates). The former is supposed to rep-
resent a mechanism for SGV-associated diseases (i.e. brain 
diseases, cancers, mosaic chromosome abnormalities), where 
as the latter is likely to be a normal process aimed at regula-
tion of cellular population size and to protect against 
aneuploidization or other unfavorable SGV [4, 5, 7, 8, 47, 
48]. Similar processes appear to underlie human aging, 
including diseases of pathological/accelerated aging [8, 10, 
18, 45]. In sum, this suggests that SGV formed during 
prenatal development are probably responsible for human 
prenatal mortality and postnatal morbidity. However, SGV 
originating from somatic mutations after birth are likely to 
be diseases-causing, as well (as exemplified by studying 
GIN and CIN in cancers). 
SGV AND HEREDITARY DISEASES 
  Genomic variations are determined according to DNA 
sequence size that is involved in a rearrangement [24]. Nu-
merous studies performed during the last decade were fo-
cused on genomic variations at DNA sequence level (gene 
mutations) [2, 3, 13, 19, 24] and copy number variations 
(CNV) [2, 3, 6, 15, 16, 23, 24, 46]. In this extent, SGV was 
continuously studied in monogenic syndromes and diseases 
associated with CNV [2, 19]. Table 2 summarizes current 
data on SGV contribution to pathogenesis of hereditary dis-
eases caused by gene mutations and CNV. 
  It is probable that some somatic CNV encompassing 
these genes are, as yet, undescribed due to extreme rarity of 390    Current Genomics, 2010, Vol. 11, No. 6  Iourov et al. 
Table 2.  SGV and Hereditary Diseases Demonstrating Somatic Gene Mutations or CNV (in Parts Adopted from [2] and [16]) 
Locus Disease Gene  CNV  Gene  Mutations 
1q21.2 Progeria  LMNA  - + 
1q44 Chronic  infantile neurologic cutaneous articular  CIAS1  - + 
2p22p21  Hereditary spastic paraplegia  SPG4  - + 
2q24 Myoclonic  epilepsy  SCN1A  - + 
2q31  Ehlers Danlos Syndrome IV  COL3A1  + - 
3p25 von-Hippel-Lindau  Disease VHL  + + 
3q13.3q21 Hypocalcemia  CASR  - + 
3q27 EEC p63  - + 
4p16.3  Skeletal disorders (syndromes)  FGFR3  - + 
4p12  Congenital central hypoventilation  PHOX2B  - + 
4q35 Facioscapulohumeral  muscular  dystrophy  D4Z4*  + ? 
5q13 Infantile spinal muscular atrophy  SMN1  - + 
6p21 Cleidocranial  dysplasia  RUNX2  - + 
7q22.1 Osteogenesis  imperfecta  COL1A2  - + 
8q12.1 CHARGE  syndrome CHD7  ? + 
9q22 Loeys-Dietz  TGFBR2  - + 
11p15.5 Costello  syndrome HRAS  - + 
11p15.1 Neonatal  diabetes  KCNJ11  - + 
12q13  Epidermolysis bullosa simplex  KRT5  - + 
12q24.1 Phenylketonuria  PAH  - + 
13q14 Retinoblastoma  RB  + + 
14q24.3 Alzheimer  disease,  early-onset  PS1  - + 
15q21.1 Marfan  FBN1  - + 
16p13 Tuberous  Sclerosis TSC2  + + 
16p13 Rubinstein-Taybi  Syndrome  CREBBP  + ? 
17q11 Neurofibromatosis  1 NF1  + + 
17q21.31 Osteogenesis  imperfecta COL1A1  - + 
17q24 Campomelic  dysplasia SOX9  + + 
22q11.2  Several hereditary syndromes  MYH9  + + 
Xp22.2p22.1 X-linked  hypophosphatemia  PHEX  - + 
Xp22.13  X-linked mental retardation (syndromic/nonsyndromic)  ARX  - + 
Xp21 Duchenne  muscular  dystrophy  DMD  + + 
Xp21  Chronic granulomatous disease  CYBB  + + 
Xp21.1  Ornithine transcarbamylase deficiency  OTC  - + 
Xp21.1 Retinitis pigmentosa  RPGR  - + 
Xp11.3 Retinitis  pigmentosa  RP2  - + 
Xq11q12 Androgen  insensitivity  AR  - + Somatic Genome Variations in Health and Disease  Current Genomics, 2010, Vol. 11, No. 6    391 
(Table 2). Contd….. 
Locus Disease Gene  CNV  Gene  Mutations 
Xq26q27.2 Lesch-Nyhan  HPRT1  - + 
Xq27 Hemophilia B  F9  - + 
Xq28 Hemophilia A  F8  + + 
Xq28 Incontinentia  pigmenti  IKBKG  + + 
Xq28 Mucopolysaccharidosis  II IDS  - + 
Xq28 Otopalatodigital  syndrome  FLNA  - + 
Xq28  Rett syndrome (males and females) and a set of other neurode-
velopmental diseases (syndromic/nonsyndromic) 
MECP2  + + 
Xq28  X-linked dyskeratosis congenita  DKC1  + + 
Xq28  X-linked mental retardation  SLC6A8  - + 
* — non-coding DNA sequences (repeats). 
the these conditions (at least some of these conditions) [2, 
19]. Additional important issue of somatic gene mutations 
and CNV is related to explanation of phenotypic difference 
between cases of the same syndrome due to different expres-
sivity in cases of SGV [19]. Finally, the list of somatic gene 
mutations and CNV is far from being complete. Further-
more, some of them appear to be benign in a proportion of 
cases [2]. 
SGV AND CHROMOSOME SYNDROMES 
  The best documented genomic variations are those de-
tected at submicroscopic and microscopic levels (subtle 
structural genomic rearrangements and chromosomal abnor-
malities) [3, 15, 24]. As mentioned above, mosaic structural 
chromosomal rearrangements are rare. There are few popula-
tion-based cytogenetic studies of these SGV suggesting them 
to be associated with milder manifestations of the corre-
sponding non-mosaic rearrangement [36]. Mosaic subtle 
structural chromosome abnormalities (undetectable by band-
ing cytogenetic techniques) are repeatedly reported but the 
incidence remain to be estimated [47, 49]. Consequently, this 
review part is primarily focused on numerical chromosome 
abnormalities (aneuploidy and poliploidy). According to 
previous review of chromosomal mosaicism [4], mosaic 
aneuploidy can be divided into three major groups: rare mo-
saic autosomal aneuploidy (chromosomes 1, 2, 3, 4, 5, 6, 7, 
10, 11, 12, 17, and 19); relatively rare mosaic autosomal 
aneuploidy (chromosomes 14, 15, 16, and 20); frequent mo-
saic autosomal aneuploidy (chromosomes 8, 9, 13, 18, 21, 
and 22). Aneuploidy of sex chromosomes is common due to 
reduced phenotypic effect as to autosomal aneuploidy [3, 4, 
15]. The majority of aneuploidy is trisomy or additional sex 
chromosomes, inasmuch as loss of an autosome leads to in-
trauterine death at the earliest stages of prenatal development 
in contrast to loss of chromosomes X and Y [4, 50, 51]. In-
terestingly, trisomies of chromosomes, rarely involved in 
aneuploidy in fetuses and liveborn infants (adults), occur at 
the same rate in preimplantation embryos as mosaic tri-
somies of other chromosomes [52]. This suggests that mo-
saic aneuploidy does not possess appreciable effect on the 
earliest stage of embryonic development. Therefore, the next 
stages of the development should exhibit high rates of chro-
mosomal mosaicism. This is supported by data on spontane-
ous abortions, 25% of which are chromosomal mosaics [50]. 
Additionally, the presence of uniparental disomy in liveborns 
is considered a confirmation of cleared prenatal mosaicism 
(confined placental mosaicism) [53]. Chromosomal mo-
saicism is also associated with asymmetry and skin pigmen-
tary anomalies [54]. For instance, some syndromes featured 
by congenital asymmetric deformations exhibit unshared 
distribution of aneuploid or polyploidy cell lines [3, 4, 54]. 
  After birth, mosaic chromosomal abnormalities are es-
sentially identified among individuals with phenotypic mani-
festation of recognizable aneuploidy (chromosomal) syn-
dromes [3, 4, 15, 55]. However, there are several reports 
about unaffected individuals with up to 30% of abnormal 
(aneuploid) cells (reviewed in [3] and [4]). The proportion of 
mosaics reflects unequal susceptibility of different chromo-
somes to mitotic non-disjunction [4, 55]. Table 3 shows mo-
saicism (mitotic non-disjunction) among cases of aneuploidy 
in humans. 
  Another well-described examples of SGV associated 
with chromosomal abnormalities (chromosomal syndromes), 
are small supernumerary marker chromosomes. Over 50% of 
cases demonstrating these chromosomal rearrangements can 
exhibit mosaicism, including tissue-specific forms [4, 56-
58]. More precise information about SGV and marker chro-
mosomes is presented in another review of this Hot Topic 
Issue (T Liehr et al. Somatic mosaicism in cases with small 
supernumerary marker chromosomes). 
  SGV demonstrate a diminished clinical effect of chromo-
some abnormalities [3, 4, 7, 15]. However, cancers, which 
are all caused by somatic mutations, are primarily associated 
with cellular (tissular) pathology [11, 13, 14, 17, 20, 41, 42]. 
Taking into account these facts, a hypothesis suggesting that 
SGV manifested as somatic chromosomal mutations (the 
commonest type of SGV) can be a source or a susceptibility 
factor for complex human diseases was proposed [3, 4, 7, 8, 
12, 15, 48]. 
SGV AND COMPLEX DISEASES 
  Currently, SGV have been described in individuals with 
brain diseases (psychiatric and neurodegenerative) [2-4, 7, 392    Current Genomics, 2010, Vol. 11, No. 6  Iourov et al. 
15-17, 19, 22, 35, 55, 59-80], autoimmune diseases [81-83], 
congenital heart diseases [84] and cancer [9, 11, 13-15, 20, 
85]. All these data is summarized by Table 4. 
  Theoretically, any mutation can be somatic leading, 
thereby, to a disease [3]. However, since genomic variations 
are classically thought to be a result of germline mutations or 
genomic rearrangements [13, 86], SGV contributions to hu-
man morbidity is poorly appreciated. In contrast, complex 
diseases appear to be likely associated with somatic muta-
tions as to monogenic syndromes and genomic disorders, 
being commonly associated with tissue-specific (or even 
“subtissue-specific”) pathology without any additional dys-
functions in other unaffected tissues [3, 4, 7, 12]. Moreover, 
SGV are able to explain some important features of complex 
disease-causing genetic alterations such as environmental 
effects or specific male-to-female ratios [4, 8, 82, 87-89]. 
Finally, to get an integral view of how SGV and other dis-
ease-causing processes interplay with each other, formation 
mechanisms of somatic mosaicism are to be established. 
SGV FORMATION MECHANISMS  
  Although formation of somatic mutations (aneuploidy 
and polyploidy) was the major focus of numerous studies in 
fields of cell biology, genetics and oncology, it is still in-
completely understood. A number of neonatal mosaics and 
cases of tissue-specific mosaicism is suggested to result from 
trisomy rescue due to placental mosaicism [3, 4, 27, 31, 53], 
but it appears to be not the case of spontaneous abortions 
[50]. In neurodegenerative and aging diseases, somatic ane-
uploidy is probably the result of cellular natural selection — 
abnormal cells possess the potential to survive and to prolif-
erate [8, 10, 45]. Studies of somatic cell division (mitosis) 
suggest that mitotic non-disjunction and anaphase lagging 
are two main mechanisms for post-zygotic aneuploidy for-
mation (aneuploidization). Numerous intracellular processes 
are assumed to be involved in improper somatic cell divi-
sions producing GIN and CIN. Among these are defects in 
kinetochore apparatus, centrosomes amplification, genetic 
and epigenetic alterations to mitotic checkpoint genes (ane-
uploidy/polyploidy) as well as abnormal DNA reparation 
and replication (structural alterations to chromosomes, ane-
uploidy, polyploidy) [3, 11, 45, 90-96]. Polyplodization fol-
lowed by multipolar cellular divisions are also hypothesized 
to be a major contributor to somatic aneuploidization associ-
ated with human diseases [96]. Nonetheless, there is still a 
lack of an integrated view on SGV formation. 
CONCLUDING REMARKS 
  In a previous issue of Current Genomics, we have hy-
pothesized that uniqueness of a cell is achieved via SGV [3]. 
Single-cell gene expression studies showing that there is no 
an average cell, because each one has own unique epigenetic 
profiling (or epigenome) [21, 97]. Here, we would like re-
peatedly adopt this idea to the cellular genome. Four years 
after the first postulation [3], important additional data on 
SGV contribution to normal and pathological human biodi-
versity have been accumulated. It was found that early hu-
man prenatal development was defined as a major source for 
SGV [5, 6]. It has been shown that neurodegeneration is me-
diated by GIN and CIN like in cancer in such devastative 
genetic brain diseases as ataxia-telangiectasia and Alz-
heimer’s disease [10, 45]. Several psychiatric diseases 
(autism and schizophrenia) have been associated with mosaic 
Table 3.  Mosaic Cases Among Common Aneuploidies (in Parts from [3, 4, 15, 55]) 
Aneuploidy  Cases of Mosaicism/Mitotic Non-Disjunction  Incidence  Disease 
Trisomy of chromosome 2  7%  unknown  — 
Trisomy of chromosome 7  57%*  unknown  — 
Trisomy of chromosome 8  50% *  >100 cases reported  Trisomy 8 
Trisomy of chromosome 13  1%  1:6000-1:29000  Patau syndrome 
Trisomy of chromosome 14  8%  ~25 cases reported  Trisomy 14 
Trisomy of chromosome 15  None  ~10 cases reported  — 
Trisomy of chromosome 16  None  ~10 cases reported  — 
Trisomy of chromosome 18  8%  1:7000  Edwards syndrome 
Trisomy of chromosome 21  5%  1:600  Down syndrome 
Trisomy of chromosome 22  2%*    Cat eye syndrome (?) 
Monosomy of chromosome X  38%* 
1:2000 
(females) 
Turner sydnrome 
Trisomy of chromosome X  20%  1:1000 (females)  Trisomy X 
47,XXY 9%  1:500 (males)  Klinefelter syndrome 
47,XYY 16%  1:800 (males)  Double Y syndrome 
* — postnatal cases suggested to be all mosaic. Somatic Genome Variations in Health and Disease  Current Genomics, 2010, Vol. 11, No. 6    393 
Table 4.  SGV in Complex Human Diseases 
Disease  Type of SGV  Key Refs 
Brain diseases (psychiatric) 
Learning disability/Mental retar-
dation 
Gene mutations, CNV mosaic aneuploidy  [2-4, 7, 15-17, 19, 22, 55] 
Mosaic structural/numerical chromosomal abnormalities: 
Partial tetrasomy 3q 
Ring chromosome 14 
Rearrangements of 15pter-q13.2 
Ring chromosome 17 
Structural abnormalities + ring chromosome 18 
Mosaic deletion 20p 
[59-61] 
[62] 
[63] 
[64, 65] 
 [66] 
[67, 68] 
[69] 
Mosaic aneuploidy (~16% of cases)  [35] 
Autism 
Fragile sites  [70, 71] 
Mosaic sex chromosome aneuploidy (blood lymphocytes)  [72-76] 
Low-level mosaic aneuploidy of chromosomes 1, 18 and X in the diseased brain  [12, 44]  Schizophrenia 
Fragile sites  [7, 77] 
Brain diseases (neurodegenerative) 
Gene mutations  [78] 
Alzheimer’s disease 
Mosaic aneuploidy of chromosome 21 in the diseased brain  [10] 
Huntington’s disease  Gene mutations (trinucleotide repeat expansion) including brain-specific mutations  [79] 
Friedreich ataxia  Gene mutations (trinucleotide repeat expansion)  [80] 
Ataxia-telangiectasia 
Mosaic aneuploidy and chromosome 14-specific breaks/additional rearranged chromo-
somes  
[45] 
Autoimmune diseases 
Primary immune deficiencies  Revertant somatic mosaicism  [81] 
Primary biliary cirrhosis  Mosaic monosomy of chromosome X  [82] 
Systemic sclerosis 
Autoimmune thyroid disease 
Mosaic monosomy of chromosome X  [83] 
Heart disease 
Gene mutations  [84] 
Congenital heart diseases 
Chromosomal abnormalities/syndromes (?)  [3, 17, 55] 
Cancers 
Almost all types of cancers 
Almost all cancers are caused by different types of SGV including ane-
uploidy/polyploidy; balanced and unbalanced structural chromosomal/genomic (subtle 
and gross) rearrangements; gene amplifications; telomere shortening; microsatellite 
instability; gene mutations; 
[9, 11, 13-15, 20, 85] 
 
(somatic) aneuploidy [35, 44]. Additionally, very recent re-
ports provided by others groups of researchers showed SGV 
implicated in the normal and abnormal brain physiology and 
aging [98-100]. These results provide essential evidences 
that neuronal DNA variation is a new feature of the human 
brain, which may contribute to neural diversity in normal 
and pathophysiological states and differences amongst indi-
viduals. Together, one can conclude that SGV research has 
proven itself sufficiently to become an important biomedical 
field that would help to understand cellular and molecular 
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